Zynerba stock rebounds after selloff driven by failed cannabis-based skin patch trial

Shares of Zynerba Pharmaceuticals Inc. rose 7% in Friday trade, recouping some of their prior-session losses, that came after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals.